Evan Seigerman
Stock Analyst at BMO Capital
(3.81)
# 623
Out of 4,870 analysts
144
Total ratings
52.63%
Success rate
7.62%
Average return
Main Sectors:
Stocks Rated by Evan Seigerman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IRON Disc Medicine | Maintains: Outperform | $112 → $120 | $51.60 | +132.56% | 6 | May 12, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Market Perform | $96 → $115 | $126.55 | -9.13% | 15 | May 6, 2025 | |
| GILD Gilead Sciences | Maintains: Outperform | $115 → $120 | $108.50 | +10.60% | 16 | Apr 17, 2025 | |
| BIIB Biogen | Maintains: Market Perform | $156 → $139 | $127.04 | +9.41% | 26 | Feb 13, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Outperform | $520 → $545 | $440.87 | +23.62% | 15 | Jan 31, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Market Perform | $57 → $61 | $46.86 | +30.17% | 11 | Nov 12, 2024 | |
| INCY Incyte | Reiterates: Underperform | $48 → $52 | $68.46 | -24.04% | 12 | Oct 30, 2024 | |
| LLY Eli Lilly and Company | Maintains: Outperform | $1,001 → $1,101 | $762.73 | +44.35% | 8 | Aug 9, 2024 | |
| GPCR Structure Therapeutics | Initiates: Outperform | $40 | $21.73 | +84.08% | 1 | Feb 28, 2023 | |
| REPL Replimune Group | Maintains: Outperform | $30 → $40 | $9.27 | +331.50% | 1 | Oct 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $757 → $788 | $509.72 | +54.59% | 17 | Aug 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $8 → $2.5 | $1.97 | +26.90% | 2 | Aug 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $263 → $243 | $289.33 | -16.01% | 6 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $12 | $4.75 | +152.63% | 2 | Mar 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $60 | $23.97 | +150.31% | 1 | Nov 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $27 | $1.36 | +1,885.29% | 2 | Aug 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $13 → $30 | $1.31 | +2,190.08% | 3 | May 12, 2020 |
Disc Medicine
May 12, 2025
Maintains: Outperform
Price Target: $112 → $120
Current: $51.60
Upside: +132.56%
Neurocrine Biosciences
May 6, 2025
Maintains: Market Perform
Price Target: $96 → $115
Current: $126.55
Upside: -9.13%
Gilead Sciences
Apr 17, 2025
Maintains: Outperform
Price Target: $115 → $120
Current: $108.50
Upside: +10.60%
Biogen
Feb 13, 2025
Maintains: Market Perform
Price Target: $156 → $139
Current: $127.04
Upside: +9.41%
Vertex Pharmaceuticals
Jan 31, 2025
Maintains: Outperform
Price Target: $520 → $545
Current: $440.87
Upside: +23.62%
Bristol-Myers Squibb Company
Nov 12, 2024
Maintains: Market Perform
Price Target: $57 → $61
Current: $46.86
Upside: +30.17%
Incyte
Oct 30, 2024
Reiterates: Underperform
Price Target: $48 → $52
Current: $68.46
Upside: -24.04%
Eli Lilly and Company
Aug 9, 2024
Maintains: Outperform
Price Target: $1,001 → $1,101
Current: $762.73
Upside: +44.35%
Structure Therapeutics
Feb 28, 2023
Initiates: Outperform
Price Target: $40
Current: $21.73
Upside: +84.08%
Replimune Group
Oct 14, 2022
Maintains: Outperform
Price Target: $30 → $40
Current: $9.27
Upside: +331.50%
Aug 4, 2022
Maintains: Outperform
Price Target: $757 → $788
Current: $509.72
Upside: +54.59%
Aug 2, 2022
Downgrades: Market Perform
Price Target: $8 → $2.5
Current: $1.97
Upside: +26.90%
Apr 28, 2022
Maintains: Market Perform
Price Target: $263 → $243
Current: $289.33
Upside: -16.01%
Mar 31, 2022
Maintains: Outperform
Price Target: $18 → $12
Current: $4.75
Upside: +152.63%
Nov 19, 2021
Initiates: Outperform
Price Target: $60
Current: $23.97
Upside: +150.31%
Aug 13, 2021
Maintains: Outperform
Price Target: $30 → $27
Current: $1.36
Upside: +1,885.29%
May 12, 2020
Maintains: Outperform
Price Target: $13 → $30
Current: $1.31
Upside: +2,190.08%